Treating Older Patients With Myeloma: Is Frailty More Important Than Age?

Video

In this peer-to-peer discussion two experts discuss the nuances and challenges of treating elderly patients with myeloma, and why therapies need to be tailored based on frailty status rather than age.

In this peer-to-peer discussion, Angela Dispenzieri, MD, of the Mayo Clinic in Rochester, Minnesota, and Ashley Rosko, MD, PhD, of the Ohio State University in Columbus, talk about the nuances and challenges of treating elderly patients with cancer, and why therapies need to be tailored based on frailty status rather than age.

At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago, Dispenzieri and Rosko spoke at an education session on treating older multiple myeloma patients that also included Sergio Giralt, MD, of Memorial Sloan Kettering Cancer Center in New York, and Maria-Victoria Mateos, MD, PhD, of the University of Salamanca Hospital in Spain.

Related Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Related Content